ReviewTranslational oncology2025
The clinical potentials of combining paclitaxel-based chemotherapy regimen with metformin in cancer treatment: A systematic review and Meta-analysis.
Review in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral clinical trials have shown that combining metformin with paclitaxel-based chemotherapy has a promising effect on various tumors but with inconsistent findings. We conducted a systematic review and meta-analysis to compare the effects of paclitaxel plus metformin versus paclitaxel-based chemotherapy alone in different organ neoplasms.
methodsA comprehensive literature search was performed in Scopus, PubMed, Web of Sciences, Embase and also Google scholar until December 2023 using MeSH keywords and all similar terms limited to randomized controlled trials (RCTs). The retrieved studies were assessed for methodological quality. Pooled standardize mean difference (SMD), odds ratio (OR) and 95 % confidence intervals (CI) of clinical outcomes were calculated using random-effects meta-analysis.
resultsOf 921 records, ultimately, 14 RCTs met the criteria for inclusion in the meta-analysis. Based on a meta-analysis findings, combination therapy of a paclitaxel-based regimen with metformin was found to be significantly associated with improved overall survival (OS) compared to the paclitaxel alone in various types of cancers (pooled SMD: 1.27; 95 % CI: 0.10, 2.43). Moreover, the metformin plus paclitaxel showed a borderline significant improvement in the pathological complete response (pCR) rate compared to the paclitaxel alone (Pooled OR: 1.74; 95 % CI: 0.96, 3.15). However, there was no significant improvement in the metformin plus paclitaxel group compared to the paclitaxel group for progression-free survival (PFS) and disease-free survival (DFS).
conclusionThe findings indicate that a combination of paclitaxel-based chemotherapy with metformin enhances OS and pCR in cancer patients. This combination therapy has the potential to improve treatment effectiveness and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.